These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
138 related items for PubMed ID: 9335081
21. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Katzman MA, Koszycki D, Bradwejn J. Depress Anxiety; 2004; 20(2):51-8. PubMed ID: 15390214 [Abstract] [Full Text] [Related]
22. Sensitivity to cholecystokinin-tetrapeptide in major depression. Koszycki D, Copen J, Bradwejn J. J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943 [Abstract] [Full Text] [Related]
23. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. Maron E, Tõru I, Vasar V, Shlik J. J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907 [Abstract] [Full Text] [Related]
24. Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects. Zwanzger P, Zavorotnyy M, Gencheva E, Diemer J, Kugel H, Heindel W, Ruland T, Ohrmann P, Arolt V, Domschke K, Pfleiderer B. Neuropsychopharmacology; 2013 Aug; 38(9):1648-54. PubMed ID: 23463151 [Abstract] [Full Text] [Related]
25. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Eser D, Schüle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, de la Motte S, Engel R, Kucher K, Rupprecht R. Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504 [Abstract] [Full Text] [Related]
26. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Tõru I, Shlik J, Maron E, Vasar V, Nutt DJ. Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242 [Abstract] [Full Text] [Related]
27. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Acta Psychiatr Scand; 1992 Oct; 86(4):273-82. PubMed ID: 1333719 [Abstract] [Full Text] [Related]
28. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Bradwejn J, Koszycki D, Couëtoux du Tertre A, Paradis M, Bourin M. Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917 [Abstract] [Full Text] [Related]
29. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Bradwejn J, LeGrand JM, Koszycki D, Bates JH, Bourin M. Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212 [Abstract] [Full Text] [Related]
30. Dose ranging study of the effects of cholecystokinin in healthy volunteers. Bradwejn J, Koszycki D, Bourin M. J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739 [Abstract] [Full Text] [Related]
31. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. van Megen HJ, Westenberg HG, den Boer JA, Haigh JR, Traub M. Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203 [Abstract] [Full Text] [Related]
32. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Bradwejn J, Koszycki D, Shriqui C. Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490 [Abstract] [Full Text] [Related]
33. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H. Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551 [Abstract] [Full Text] [Related]
34. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS. Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078 [Abstract] [Full Text] [Related]
35. Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Brambilla F, Bellodi L, Arancio C, Nobile P, Perna G. Psychoneuroendocrinology; 1995 Aug; 20(1):11-9. PubMed ID: 7838899 [Abstract] [Full Text] [Related]
36. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, Kellner M. Neuropsychopharmacology; 2007 Jan; 32(1):232-8. PubMed ID: 17035932 [Abstract] [Full Text] [Related]
37. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Brambilla F, Perna G, Garberi A, Nobile P, Bellodi L. Psychoneuroendocrinology; 1995 Jan; 20(1):1-9. PubMed ID: 7838898 [Abstract] [Full Text] [Related]
38. Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. Kellner M, Knaudt K, Jahn H, Holsboer F, Wiedemann K. J Psychiatr Res; 1998 Jan; 32(1):37-48. PubMed ID: 9693999 [Abstract] [Full Text] [Related]
39. Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. Tancer ME, Stein MB, Uhde TW. Biol Psychiatry; 1993 Nov 01; 34(9):591-5. PubMed ID: 8292687 [Abstract] [Full Text] [Related]
40. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H. Am J Psychiatry; 1992 Jul 01; 149(7):962-4. PubMed ID: 1609879 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]